240 related articles for article (PubMed ID: 29334502)
1. Risk of Hepatitis B Virus Reactivation Among Patients Treated With Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection.
Yanny BT; Latt NL; Saab S; Han S; Choi G; Kramer J; Sahota AK
J Clin Gastroenterol; 2018; 52(10):908-912. PubMed ID: 29334502
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected With HBV.
Liu CJ; Chuang WL; Sheen IS; Wang HY; Chen CY; Tseng KC; Chang TT; Massetto B; Yang JC; Yun C; Knox SJ; Osinusi A; Camus G; Jiang D; Brainard DM; McHutchison JG; Hu TH; Hsu YC; Lo GH; Chu CJ; Chen JJ; Peng CY; Chien RN; Chen PJ
Gastroenterology; 2018 Mar; 154(4):989-997. PubMed ID: 29174546
[TBL] [Abstract][Full Text] [Related]
3. Reactivation of occult HBV infection in an HIV/HCV Co-infected patient successfully treated with sofosbuvir/ledipasvir: a case report and review of the literature.
Fabbri G; Mastrorosa I; Vergori A; Mazzotta V; Pinnetti C; Grisetti S; Zaccarelli M; Ammassari A; Antinori A
BMC Infect Dis; 2017 Mar; 17(1):182. PubMed ID: 28249574
[TBL] [Abstract][Full Text] [Related]
4. No evidence of hepatitis B virus reactivation in patients with resolved infection treated with direct-acting antivirals for hepatitis C in a large real-world cohort.
Mücke VT; Mücke MM; Peiffer KH; Weiler N; Welzel TM; Sarrazin C; Zeuzem S; Berger A; Vermehren J
Aliment Pharmacol Ther; 2017 Aug; 46(4):432-439. PubMed ID: 28627791
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis B virus reactivation among hepatitis C patients treated with direct-acting antiviral therapies in routine clinical practice.
Loggi E; Gitto S; Galli S; Minichiello M; Conti F; Grandini E; Scuteri A; Vitale G; Di Donato R; Cursaro C; Furlini G; Andreone P
J Clin Virol; 2017 Aug; 93():66-70. PubMed ID: 28654775
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of hepatitis B reactivation among 62,920 veterans treated with oral hepatitis C antivirals.
Belperio PS; Shahoumian TA; Mole LA; Backus LI
Hepatology; 2017 Jul; 66(1):27-36. PubMed ID: 28240789
[TBL] [Abstract][Full Text] [Related]
7. Potential risk of HBV reactivation in patients with resolved HBV infection undergoing direct-acting antiviral treatment for HCV.
Ogawa E; Furusyo N; Murata M; Toyoda K; Hayashi T; Ura K
Liver Int; 2018 Jan; 38(1):76-83. PubMed ID: 28618152
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response.
Terrault NA; Zeuzem S; Di Bisceglie AM; Lim JK; Pockros PJ; Frazier LM; Kuo A; Lok AS; Shiffman ML; Ben Ari Z; Akushevich L; Vainorius M; Sulkowski MS; Fried MW; Nelson DR;
Gastroenterology; 2016 Dec; 151(6):1131-1140.e5. PubMed ID: 27565882
[TBL] [Abstract][Full Text] [Related]
9. A case of acute hepatitis B in a chronic hepatitis C patient after daclatasvir and asunaprevir combination therapy: hepatitis B virus reactivation or acute self-limited hepatitis?
Hayashi K; Ishigami M; Ishizu Y; Kuzuya T; Honda T; Nishimura D; Goto H; Hirooka Y
Clin J Gastroenterol; 2016 Aug; 9(4):252-6. PubMed ID: 27329484
[TBL] [Abstract][Full Text] [Related]
10. No Evidence of Reactivation of Hepatitis B Virus Among Patients Treated With Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection.
Sulkowski MS; Chuang WL; Kao JH; Yang JC; Gao B; Brainard DM; Han KH; Gane E
Clin Infect Dis; 2016 Nov; 63(9):1202-1204. PubMed ID: 27486112
[TBL] [Abstract][Full Text] [Related]
11. Rare clinically significant hepatic events and hepatitis B reactivation occur more frequently following rather than during direct-acting antiviral therapy for chronic hepatitis C: Data from a national US cohort.
Serper M; Forde KA; Kaplan DE
J Viral Hepat; 2018 Feb; 25(2):187-197. PubMed ID: 28845882
[TBL] [Abstract][Full Text] [Related]
12. Low incidence of hepatitis B virus reactivation and subsequent hepatitis in patients with chronic hepatitis C receiving direct-acting antiviral therapy.
Tamori A; Abiru S; Enomoto H; Kioka K; Korenaga M; Tani J; Enomoto M; Sugiyama M; Masaki T; Kawada N; Yatsuhashi H; Nishiguchi S; Mizokami M
J Viral Hepat; 2018 May; 25(5):608-611. PubMed ID: 29194858
[TBL] [Abstract][Full Text] [Related]
13. Reactivation of hepatitis B in patients of chronic hepatitis C with hepatitis B virus infection treated with direct acting antivirals.
Yeh ML; Huang CF; Hsieh MH; Ko YM; Chen KY; Liu TW; Lin YH; Liang PC; Hsieh MY; Lin ZY; Chen SC; Huang CI; Huang JF; Kuo PL; Dai CY; Yu ML; Chuang WL
J Gastroenterol Hepatol; 2017 Oct; 32(10):1754-1762. PubMed ID: 28230928
[TBL] [Abstract][Full Text] [Related]
14. Direct-acting antivirals and hepatitis B virus (HBV) reactivation in co-infected HBV/HCV kidney-transplant recipients.
Pol S; Marion O; Vallet-Pichard A; Meritet JF; Sauné K; Alric L; Kamar N
Transpl Infect Dis; 2018 Jun; 20(3):e12864. PubMed ID: 29512231
[TBL] [Abstract][Full Text] [Related]
15. Direct-acting antiviral treatment in adults infected with hepatitis C virus: Reactivation of hepatitis B virus coinfection as a further challenge.
De Monte A; Courjon J; Anty R; Cua E; Naqvi A; Mondain V; Cottalorda J; Ollier L; Giordanengo V
J Clin Virol; 2016 May; 78():27-30. PubMed ID: 26967675
[TBL] [Abstract][Full Text] [Related]
16. Eight-week ledipasvir/sofosbuvir in non-cirrhotic, treatment-naïve hepatitis C genotype-1 patients with hepatitis C virus-RNA < 6 million: Single center, real world effectiveness and safety.
Latt NL; Yanny BT; Gharibian D; Gevorkyan R; Sahota AK
World J Gastroenterol; 2017 Jul; 23(26):4759-4766. PubMed ID: 28765697
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis B Virus Reactivation Associated With Direct-Acting Antiviral Therapy for Chronic Hepatitis C Virus: A Review of Cases Reported to the U.S. Food and Drug Administration Adverse Event Reporting System.
Bersoff-Matcha SJ; Cao K; Jason M; Ajao A; Jones SC; Meyer T; Brinker A
Ann Intern Med; 2017 Jun; 166(11):792-798. PubMed ID: 28437794
[TBL] [Abstract][Full Text] [Related]
18. Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir-experienced, NS5A treatment-naïve patients: Findings from two randomized trials.
Tam E; Luetkemeyer AF; Mantry PS; Satapathy SK; Ghali P; Kang M; Haubrich R; Shen X; Ni L; Camus G; Copans A; Rossaro L; Guyer B; Brown RS;
Liver Int; 2018 Jun; 38(6):1010-1021. PubMed ID: 29091342
[TBL] [Abstract][Full Text] [Related]
19. Incidence and clinical characteristics of hepatitis B virus reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for rheumatoid arthritis.
Tien YC; Yen HH; Chiu YM
Clin Exp Rheumatol; 2017; 35(5):831-836. PubMed ID: 28375829
[TBL] [Abstract][Full Text] [Related]
20. Ledipasvir-sofosbuvir for treating Japanese patients with chronic hepatitis C virus genotype 2 infection.
Asahina Y; Itoh Y; Ueno Y; Matsuzaki Y; Takikawa Y; Yatsuhashi H; Genda T; Ikeda F; Matsuda T; Dvory-Sobol H; Jiang D; Massetto B; Osinusi AO; Brainard DM; McHutchison JG; Kawada N; Enomoto N
Liver Int; 2018 Sep; 38(9):1552-1561. PubMed ID: 29297980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
